Projects

Chosen filters:
Chosen filters:

1 - 10 of 679 results

Sorteren op
Search term:

From hit to lead: inducing basal autophagy for treating cardiovascular diseases. University of Antwerp

Pieter-Jan Guns
Physiopharmacology (PHYSPHAR)
Autophagy is a normal physiological process that maintains intracellular homeostasis by degrading unnecessary or dysfunctional cellular components in lysosomes. This way, autophagy supports cell survival in unfavourable conditions and represents a reparative and life-sustaining process. Impaired autophagy is increasingly recognized as a hallmark of aging and of multiple human pathological conditions, including cardiovascular disease. Moreover, ...

Joint Action on Cardiovascular Diseases and Diabetes (JACARDI). University of Antwerp

Edwin Wouters
Carlo Besta Neurological Institute, Paolo Giaccone University Hospital (AOUP), Aragonese Institute of Health Sciences, University of Ljubljana, Health Research Institute Hospital La Fe, Katholieke Universiteit Leuven, Bocconi University, Nantes University Hospital, Health Research Institute Valencia (INCLIVA), National Institute for Elderly Hospitalization and Care (INRCA), Sciensano, Gottsegen National Cardiovascular Center, Ministry of Health Greece, Ministry of Health Portugal, University of Florence, National Institute of Public Health, University of Turin, Finnish Institute for Health and Welfare (THL), IRCCS Mother and Child Burlo Garofolo, Croí The West of Ireland Cardiac Foundation, Ministry of Health of the Republic Cyprus, Ministry for Health - Government of Malta, Finnish Institute of Occupational Health, National Institute of Public Health, Poznan University of Medical Sciences, Institute for Health and Biomedical Research of Alicante, New University of Lisbon, Italian Higher Institute of Health, Kronikgune Institute for Health Systems Research, Health Research Institute IDIVAL at Marqués de Valdecilla University Hospital, Center of Public Health of the Ministry of Health of Ukraine, Latvian Biomedical Research and Study Centre (LBMC), Norwegian Directorate of Health, National Institute of Public Health, Toulouse University Hospital, Autonomous Province of Trento, Hospices Civils de Lyon, Portuguese Association for the Protection of Diabetics (APDP), Agostino Gemelli University Polyclinic, Istituti Clinici Scientifici Maugeri Spa Società Benefit, Tours Regional University Hospital, Croatian Institute of Public Health, Agence Nationale de Santé Publique France, University of Eastern Finland, Finnish Diabetes Association, Medical University of Silesia, Research Institute Hospital 12 de Octubre (i+12), Directorate of Health Iceland, Centre for Population, Family and Health
The Joint Action on CARdiovascular diseases and DIabetes (JACARDI) aims to reduce the burden of cardiovascular disease (CVD) and diabetes (DM) in EU countries, both at individual and societal level. JACARDI is designed to integrate validated best practices and/or (cost-)effective interventions across countries and regions through transnational pilot initiatives, complementing and reinforcing existing policies and programs. The initiative covers ...

RADical reduction of OXidative stress in cardiovascular diseases. KU Leuven

Stefan Janssens
Cardiology

Cardiovascular disease (CVD) constitutes a major and increasing health burden in developed countries. The prediction is that the prevalence of these conditions will increase by ~60% over the next 20 years. Therefore, the development of novel treatments for patients with CVD becomes more and more urgent. Oxidative stress is an important molecular contributor to the pathogenesis of CVD. However, oxidative stress-related therapeutic strategies ...

How do cardiovascular diseases and their treatments affect the microstructural-mechanical relationship? An advanced 3D microstructural analysis & modeling approach KU Leuven

Nele Famaey
BioMechanics (BMe)

Cardiovascular diseases are still the leading cause of death worldwide. Treatment options such as intravascular stent deposition or balloon angioplasty often tend to fail. The hypothesis is that this failure is partly due the application of too large mechanical forces on the vascular tissue during treatment. However, the exact mechanisms are not yet fully understood. To better understand these mechanisms and to evaluate ...

Thromboinflammation in Cardiovascular Diseases KU Leuven

Thomas Vanassche
Cardiology, Centre for Molecular and Vascular Biology

Our blood clotting system protects us from bleeding, and is crucial for survival. On the other hand, undesired activation of blood clotting is the most important cause of death. Indeed, when blood clots form inside the blood vessels, it can cause heart infarcts, stroke, or obstruction of the lung blood vessels.

Luckily, we have effective drugs that prevent blood clotting. These drugs are used to prevent deaths ...

Nanobody-based inhibitors of connexin hemichannels and pannexin channels as novel therapeutics for the treatment of inflammatory hepatic and cardiovascular diseases. Vrije Universiteit Brussel

Mathieu Vinken
University of Geneva, Department of Bio-engineering Sciences, Pharmaceutical and Pharmacological Sciences
Production of nanobodies raised against transmembrane proteins that are difficult to purify still is a technical challenge. Among those are connexin43 cCx43) and pannexin1 (Panx1), which form (hemi) channels in the plasma membrane. These (hemi)channels mediate extracellular signaling and have recently emerged as key players in inflammation. This carries translational relevance, as (hemi) channel inhibition could represent a novel strategy for ...

Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular and hepatic diseases Vrije Universiteit Brussel

Mathieu Vinken
Chemistry, Pharmaceutical and Pharmacological Sciences, Liver Connexin and Pannexin Research Group
The modulation of membrane-bound proteins by drugs is receiving increasing attention from both academia and industry. Among such proteins are pannexin1 (Panx1), connexin43 (Cx43) and connexin32 (Cx32) that form hemichannels at the plasma membrane surface. These hemichannels mediate cellular communication and have emerged as key players in inflammation. This carries translational relevance, as hemichannel inhibition could represent an innovative ...

Activation of the contact pathway of coagulation in cardiovascular diseases. KU Leuven

Thomas Vanassche
Centre for Molecular and Vascular Biology

Our blood clotting system protects us from bleeding, and is crucial for survival. On the other hand, undesired activation of blood clotting is the most important cause of death. Indeed, when blood clots form inside the blood vessels, it can cause heart infarcts, stroke, or obstruction of the lung blood vessels.
Luckily, we have effective drugs that prevent blood clotting. These drugs are used to prevent deaths and ...

JACARDI Joint Action on CARdiovascular Diseases and DIabetes KU Leuven

Geert Goderis
Academic Center for General Practice

The JACARDI project aligns with the objectives of the European Union Health Programme (EU4H) by focusing on the reduction of NCDs at both individual and societal levels. It seeks to reduce the burden of CVD and DM while increasing awareness of related risks and the acceptance of innovative lifestyle interventions.

The project’s relevance extends to addressing the diverse needs of the people in Europe, harmonizing health systems, and ...